

Amendments to the Claims:

The listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original) A chimeric polypeptide which is engineered to include a domain comprising a sequence that directs the attachment of at least one glycosylphosphatidylinositol molecule, wherein said polypeptide is not a ligand binding domain of a cytokine receptor and is for use as a pharmaceutical.
2. (Previously presented) The polypeptide according to claim 1 wherein said polypeptide is a cytokine or variant thereof.
3. (Previously presented) The polypeptide according to claim 1 wherein said domain comprises the amino acid sequence: PSPTPTETAT PSPTPKPTST PEETEAPSSA TTLISPLSLI VIFISFVLLI. (SEQ ID NO: 12).
4. (Withdrawn) The polypeptide according to claim 1 wherein said domain comprises the amino acid sequence: LVPRGSIEGR GTSITAYNSE GESAEFFFL ILLLLLVLV. (SEQ ID NO: 13)
5. (Withdrawn) The polypeptide according to claim 1 wherein said domain comprises the amino acid sequence: TSITAYKSE GESAEFFFL ILLLLLVLV. (SEQ ID NO: 14)
6. (Previously presented) The polypeptide according to claim 1 wherein said polypeptide includes at least one glycosylphosphatidylinositol molecule.
7. (Previously presented) The polypeptide according to claim 2 wherein said polypeptide is selected from the group consisting of: growth hormone; leptin; erythropoietin; prolactin; TNF, interleukins (IL), IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-9, IL-10, IL-11; the p35 subunit of IL-12, IL-13, IL-15; granulocyte colony stimulating factor (G-CSF); granulocyte macrophage colony stimulating factor

(GM-CSF); ciliary neurotrophic factor (CNTF); cardiotrophin-1 (CT-1); leukemia inhibitory factor (LIF); oncostatin M (OSM); interferon, IFN.alpha. and IFN.gamma.,

8. (Previously presented) The polypeptide according to claim 1 wherein said polypeptide has been modified by addition, deletion or substitution of at least one amino acid residue to provide a sequence variant of said polypeptide.

9. (Previously presented) The polypeptide according to claim 8 wherein said variant polypeptide is growth hormone which has been modified in at least one growth hormone receptor binding domain.

10. (Previously presented) The polypeptide according to claim 9 wherein said growth hormone receptor binding domain is in site 1 of growth hormone.

11. (Previously presented) The polypeptide according to claim 9 wherein said growth hormone receptor binding domain is modified in site 2 of growth hormone.

12. (Previously presented) The polypeptide according to claim 9 wherein said growth hormone receptor binding domain is modified in site 1 and site 2 of growth hormone.

13. (Withdrawn) The polypeptide according to claim 10 wherein said modification is selected from the group consisting of: histidine 18 with alanine or aspartic acid; and/or histidine 21 with asparagine; and/or glutamine 22 with alanine; and/or phenylalanine 25 with alanine; and/or aspartic acid 26 with alanine; and/or glutamine 29 with alanine; and/or glutamic acid 167 with alanine; and/or aspartic acid 171 with serine; and/or lysine 172 with serine or alanine; and/or isoleucine 179 with tyrosine, as represented by the growth hormone amino acid sequence in FIG. 2 (amino acids 21-254 of SEQ ID NO: 2).

14. (Withdrawn) The polypeptide according to claim 13 wherein said modification consists of the the amino acid substitutions: histidine 18 aspartic acid; histidine

21 asparagine; arginine 167 asparagine; aspartic acid 171 arginine; glutamic acid 174 serine; and isoleucine 179 threonine; as represented by the GH amino acid sequence in FIG. 2 (amino acids 21-254 of SEQ ID NO: 2).

15. (Withdrawn) The polypeptide according to claim 13 wherein said modification consists of the amino acid substitutions: histidine 18 alanine; glutamine 22 alanine; phenylalanine 25 alanine; aspartic acid 26 alanine; glutamine 29 alanine; glutamic acid 65 alanine; lysine 168 alanine; and glutamic acid 174 alanine; as represented by the GH amino acid sequence in FIG. 2 (amino acids 21-254 of SEQ ID NO: 2).

16. (Previously presented) The polypeptide according to claim 11 wherein said site 2 modification is to amino acid residue glycine 120 of the amino acid sequence presented in FIG. 2 (amino acids 21-254 of SEQ ID NO: 2).

17. (Previously presented) The polypeptide according to claim 16 wherein said site 2 modification is a substitution of glycine for an amino acid selected from the group consisting of: arginine; alanine; lysine; tryptophan; tyrosine; phenylalanine; and glutamic acid.

18. (Previously presented) The polypeptide according to claim 17 wherein said site 2 substitution is glycine 120 for arginine or lysine or alanine.

19-42. (Cancelled)